PBM
Psyence Biomedical Ltd.
Biotechnology
Market Cap$39M
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PBM vs ATAI
Revenue, margins, valuation, and 5-year total return — side by side.
ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$964M
5Y Perf.+125.3%
PBM vs ATAI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PBM | ATAI |
|---|---|---|
| Industry | Biotechnology | Medical - Pharmaceuticals |
| Market Cap | $39M | $964M |
| Revenue (TTM) | $0.00 | $3M |
| Net Income (TTM) | $-25M | $-154M |
| Gross Margin | — | -259.1% |
| Operating Margin | — | -34.6% |
| Total Debt | $10M | $25M |
| Cash & Equiv. | $763K | $18M |
PBM vs ATAI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PBM
ATAI
| Stock | Jan 24 | May 26 | Return |
|---|---|---|---|
| Psyence Biomedical … (PBM) | 100 | 0.1 | -99.9% |
| Atai Beckley N.V (ATAI) | 100 | 225.3 | +125.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PBM vs ATAI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATAI leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Psyence Biomedical Ltd. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
PBM
Psyence Biomedical Ltd.
The Quality Compounder
PBM is the clearest fit if your priority is quality.
- -4.5% margin vs ATAI's -51.1%
Best for: quality
ATAI
Atai Beckley N.V
The Income Pick
ATAI carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.48
- Rev growth -1.9%, EPS growth -272.0%, 3Y rev CAGR -75.3%
- -47.7% 10Y total return vs PBM's -100.0%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATAI | -1.9% revenue growth vs PBM's -76.5% |
| Quality / Margins | PBM | -4.5% margin vs ATAI's -51.1% |
| Stability / Safety | ATAI | Beta 1.48 vs PBM's 3.27 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATAI | +188.5% vs PBM's -76.6% |
| Efficiency (ROA) | ATAI | -64.3% ROA vs PBM's -23K%, ROIC -45.0% vs -1.7% |
PBM vs ATAI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
PBM vs ATAI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLATAILAGGINGPBM
PBMPsyence Biomedical Lt…
1leads
ATAIAtai Beckley N.V
4leads
6 Total Categories
CATEGORYLEADERvs PBMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATAI1/1
Valuation MetricsMultiples, price ratios, and targets
ATAI1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PBM6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ATAI5/6
Risk & VolatilityBeta, volatility, and downside exposure
ATAI2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATAI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATAI and PBM operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | PBMPsyence Biomedica… | ATAIAtai Beckley N.V |
|---|---|---|
| RevenueTrailing 12 months | $0 | $3M |
| EBITDAEarnings before interest/tax | -$2M | -$103M |
| Net IncomeAfter-tax profit | -$25M | -$154M |
| Free Cash FlowCash after capex | -$1M | -$90M |
| Gross MarginGross profit ÷ Revenue | — | -2.6% |
| Operating MarginEBIT ÷ Revenue | — | -34.6% |
| Net MarginNet income ÷ Revenue | — | -51.1% |
| FCF MarginFCF ÷ Revenue | — | -29.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -27.9% | -75.0% |
ATAI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ATAI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | PBMPsyence Biomedica… | ATAIAtai Beckley N.V |
|---|---|---|
| Market CapShares × price | $39M | $964M |
| Enterprise ValueMkt cap + debt − cash | $49M | $971M |
| Trailing P/EPrice ÷ TTM EPS | -0.77x | -4.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3130.37x |
| Price / BookPrice ÷ Book value/share | — | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
ATAI leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
PBM leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
PBM delivers a -43.8% return on equity — every $100 of shareholder capital generates $-44 in annual profit, vs $-96 for ATAI. On the Piotroski fundamental quality scale (0–9), PBM scores 3/9 vs ATAI's 2/9, reflecting mixed financial health.
| Metric | PBMPsyence Biomedica… | ATAIAtai Beckley N.V |
|---|---|---|
| ROE (TTM)Return on equity | -43.8% | -96.4% |
| ROA (TTM)Return on assets | -22525.0% | -64.3% |
| ROICReturn on invested capital | -1.7% | -45.0% |
| ROCEReturn on capital employed | -2.4% | -50.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.21x |
| Net DebtTotal debt minus cash | $10M | $7M |
| Cash & Equiv.Liquid assets | $762,799 | $18M |
| Total DebtShort + long-term debt | $10M | $25M |
| Interest CoverageEBIT ÷ Interest expense | -32.41x | -68.93x |
PBM leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ATAI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATAI five years ago would be worth $2,016 today (with dividends reinvested), compared to $3 for PBM. Over the past 12 months, ATAI leads with a +188.5% total return vs PBM's -76.6%. The 3-year compound annual growth rate (CAGR) favors ATAI at 25.9% vs PBM's -93.5% — a key indicator of consistent wealth creation.
| Metric | PBMPsyence Biomedica… | ATAIAtai Beckley N.V |
|---|---|---|
| YTD ReturnYear-to-date | +20.4% | +3.6% |
| 1-Year ReturnPast 12 months | -76.6% | +188.5% |
| 3-Year ReturnCumulative with dividends | -100.0% | +99.5% |
| 5-Year ReturnCumulative with dividends | -100.0% | -79.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | -47.7% |
| CAGR (3Y)Annualised 3-year return | -93.5% | +25.9% |
ATAI leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ATAI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATAI is the less volatile stock with a 1.48 beta — it tends to amplify market swings less than PBM's 3.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATAI currently trades 59.4% from its 52-week high vs PBM's 8.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PBMPsyence Biomedica… | ATAIAtai Beckley N.V |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.27x | 1.48x |
| 52-Week HighHighest price in past year | $71.94 | $6.75 |
| 52-Week LowLowest price in past year | $0.69 | $1.29 |
| % of 52W HighCurrent price vs 52-week peak | +8.4% | +59.4% |
| RSI (14)Momentum oscillator 0–100 | 51.7 | 51.5 |
| Avg Volume (50D)Average daily shares traded | 2.9M | 6.0M |
ATAI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PBMPsyence Biomedica… | ATAIAtai Beckley N.V |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $12.00 |
| # AnalystsCovering analysts | — | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATAI leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). PBM leads in 1 (Profitability & Efficiency).
Best OverallAtai Beckley N.V (ATAI)Leads 4 of 6 categories
Loading custom metrics...
PBM vs ATAI: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PBM or ATAI a better buy right now?
Analysts rate Atai Beckley N.
V (ATAI) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PBM or ATAI?
Over the past 5 years, Atai Beckley N.
V (ATAI) delivered a total return of -79. 8%, compared to -100. 0% for Psyence Biomedical Ltd. (PBM). Over 10 years, the gap is even starker: ATAI returned -47. 7% versus PBM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PBM or ATAI?
By beta (market sensitivity over 5 years), Atai Beckley N.
V (ATAI) is the lower-risk stock at 1. 48β versus Psyence Biomedical Ltd. 's 3. 27β — meaning PBM is approximately 120% more volatile than ATAI relative to the S&P 500.
04Which is growing faster — PBM or ATAI?
On earnings-per-share growth, the picture is similar: Atai Beckley N.
V grew EPS -272. 0% year-over-year, compared to -1126. 6% for Psyence Biomedical Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PBM or ATAI?
Psyence Biomedical Ltd.
(PBM) is the more profitable company, earning 0. 0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PBM leads at 0. 0% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PBM or ATAI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PBM or ATAI better for a retirement portfolio?
For long-horizon retirement investors, Atai Beckley N.
V (ATAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Psyence Biomedical Ltd. (PBM) carries a higher beta of 3. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATAI: -47. 7%, PBM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PBM and ATAI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.